Hepadnavirus cores
AssigneeBristol-Myers Squibb Company
InventorsMaria Seifer, Robert Hamatake, David N. Standring
Life of this patent
Estimating the term…
Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsMaria Seifer, Robert Hamatake, David N. Standring
Estimating the term…
Provided in one embodiment is a non-infectious, recombinant hepadnavirus core particle composition comprising isolated hepadnavirus core particles, template RNA encapsidated in the same core particles and hepadnavirus polymerase encapsidated in the same core particles, wherein, upon addition of deoxynucleoside triphosphates to the composition, the hepadnavirus polymerase incorporates deoxynucleotides from the added deoxynucleosides into reverse transcripts of the template RNA beginning with the first deoxynucleotide of the reverse transcript or within about 10 deoxynucleotides of the first deoxynucleotide of the reverse transcript. Another embodiment provides hapadnaviral core particles with all three functional components: (1) P; (2) C; and (3) a nucleic acid that serves as a template. These core particles include for example (a) recombinant, insect-cell-derived core particles, (b) core particles produced in cells contacted with a reverse transcriptase inhibitor, and (c) core particles that are especially suitable for assays for (+)-strand synthesis.
A non-infectious, recombinant hepadnavirus core particle composition comprising
A method of preparing a non-infectious, recombinant hepadnavirus core particle composition comprising (a) hepadnavirus core particles, (b) template nucleic acid encapsidated in core particles and (c) hepadnavirus polymerase encapsidated in core particles, wherein, upon addition of deoxynudeoside triphosphates to the composition, the hepadnavirus polymerase incorporates deoxynucleotides into reverse transcripts of the template nucleic acid beginning with the first deoxynucleotide of the reverse transcript or within about ten deoxynucleotides of the first deoxynucleotide of the reverse transcript, the method comprising
A non-infectious, recombinant hepadnavirus core particle composition isolated from cells, wherein said cells are transformed with one or more recombinant vectors encoding hepadnavirus core protein and hepadnavirus polymerase and contacted with a reverse-transcriptase inhibiting effective amount of a reverse transcriptase inhibitor, and wherein the core particles comprise hepadnavirus polymerase and template nucleic acid encapsidated therein such that, upon addition of deoxynucleoside triphosphates to the composition, the deoxynucleotides are incorporated into DNA.
A non-infectious, recombinant hepadnavirus core particle composition isolated from insect cells transformed with one or more recombinant baculoviruses encoding hepadnavirus core protein and hepadnavirus polymerase, wherein the core particles comprise hepadnavirus polymerase and template nucleic acid encapsidated therein such that, upon addition of deoxynucleoside triphosphates to the composition, the deoxynucleotides are incorporated into DNA.
A non-infectious, recombinant hepadnavirus core particle composition comprising core particles that comprise hepadnavirus polymerase and nucleic acid encapsidated therein such that, upon addition of deoxynucleoside triphosphates to the composition, deoxynucleotides are incorporated into a substantial distribution of (+)-strand nucleic acids.
Dependencies are inferred from the claim text.